Wolfgang R. Sperr

Vienna, Austria

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 219 publications

Subtype-specific outcome after allogeneic hematopoietic cell transplantation in advanced systemic mastocytosis: a registry study of the European competence network on mastocytosis.

Subtype-specific outcome after allogeneic hematopoietic cell transplantation in advanced systemic mastocytosis: a registry study of the European competence network on mastocytosis.

Journal: Experimental hematology & oncology

Published: June 21, 2026

Management of critically ill cancer patients. Expert consensus statement of the "Intensive Care for Hematology and Oncology Patients" (iCHOP) Working Group of the German Society of Hematology and Oncology (DGHO), Austrian Society of Hematology and Oncology (OeGHO), German Society for Medical Intensive Care Medicine and Emergency Medicine (DGIIN), and Austrian Society of Medical and General Intensive Care and Emergency Medicine (ÖGIAIN).

Management of critically ill cancer patients. Expert consensus statement of the "Intensive Care for Hematology and Oncology Patients" (iCHOP) Working Group of the German Society of Hematology and Oncology (DGHO), Austrian Society of Hematology and Oncology (OeGHO), German Society for Medical Intensive Care Medicine and Emergency Medicine (DGIIN), and Austrian Society of Medical and General Intensive Care and Emergency Medicine (ÖGIAIN).

Journal: European journal of cancer (Oxford, England : 1990)

Published: June 01, 2026

Outcomes and prognostic factors in patients with systemic mastocytosis and an associated myeloid neoplasm: an international ECNM registry study.

Outcomes and prognostic factors in patients with systemic mastocytosis and an associated myeloid neoplasm: an international ECNM registry study.

Journal: Journal of hematology & oncology

Published: March 15, 2026

Serial Determinations of Molecular Aberrations in Patients with Acute Myeloid Leukemia During Treatment with Oral Decitabine/Cedazuridine.

Serial Determinations of Molecular Aberrations in Patients with Acute Myeloid Leukemia During Treatment with Oral Decitabine/Cedazuridine.

Journal: Cancers

Published: March 01, 2026

Unexplained bleeding tendency and scleroderma-like skin changes: a diagnostic journey to vitamin C deficiency.

Unexplained bleeding tendency and scleroderma-like skin changes: a diagnostic journey to vitamin C deficiency.

Journal: Research and practice in thrombosis and haemostasis

Published: December 23, 2025

Systemic Mastocytosis, KIT and the Effects of KIT Tyrosine Kinase Inhibitors on Mast Cell and Basophil Activation.

Systemic Mastocytosis, KIT and the Effects of KIT Tyrosine Kinase Inhibitors on Mast Cell and Basophil Activation.

Journal: Current allergy and asthma reports

Published: October 05, 2025

Soluble FcεRI is increased in advanced mastocytosis and acts as a negative regulator of mast cell expansion and activation.

Soluble FcεRI is increased in advanced mastocytosis and acts as a negative regulator of mast cell expansion and activation.

Journal: The Journal of allergy and clinical immunology

Published: September 11, 2025

Efficacy and safety of avapritinib in advanced systemic mastocytosis: 4-year follow-up of the PATHFINDER study.

Efficacy and safety of avapritinib in advanced systemic mastocytosis: 4-year follow-up of the PATHFINDER study.

Journal: Blood advances

Published: June 20, 2025

Efficacy and safety of avapritinib in advanced systemic mastocytosis: 4-year follow-up of the PATHFINDER study.

Efficacy and safety of avapritinib in advanced systemic mastocytosis: 4-year follow-up of the PATHFINDER study.

Journal: Blood advances

Published: June 20, 2025

Efficacy assessment following shortened venetoclax exposure in AML patients treated with venetoclax plus hypomethylating agents: a real-world, multicentric study.

Efficacy assessment following shortened venetoclax exposure in AML patients treated with venetoclax plus hypomethylating agents: a real-world, multicentric study.

Journal: Blood cancer journal

Published: June 17, 2025

Hereditary alpha-tryptasemia - a potential cause of severe anaphylactic reactions and a modifier of mast cell diseases.

Hereditary alpha-tryptasemia - a potential cause of severe anaphylactic reactions and a modifier of mast cell diseases.

Journal: Swiss medical weekly

Published: June 01, 2025

Tissue-Resident Myeloid and Histiocytic Cells in Health and Disease: Novel Emerging Concepts.

Tissue-Resident Myeloid and Histiocytic Cells in Health and Disease: Novel Emerging Concepts.

Journal: American journal of hematology

Published: May 30, 2025

Showing 1-12 of 219

Last Updated: 09/26/2026